Prompt depression care linked to lower cancer mortality

Clinical takeaway: Ask about depression when cancer is diagnosed and treat psychotherapy referral as time-sensitive: earlier starts tracked with lower cancer death risk. 

Depression is easy to miss in a patient newly diagnosed with cancer: fatigue, trouble concentrating, and fading interest read as effects of the malignancy or its treatment. And patients whose depression is missed may be losing more than quality of life. But one in five patients with cancer carries a depression diagnosis. 

Mental health care often sits outside oncology workflows, so treatment reaches many late or not at all. Whether depression itself bears on cancer survival, and whether treating it early is tied to better outcomes, has been harder to establish. A new analysis presented at the American Society for Radiation Oncology annual meeting tests both. 

Patients with depression who began psychotherapy within four weeks of their cancer diagnosis had a 21% lower risk of dying from their cancer. Just 3% started therapy that soon, and only 4.6% had by 12 weeks. The association weakened with later starts, to 13% lower risk at eight weeks and 12% at 12 weeks. Five-year cancer-specific mortality ran 31% among patients who received psychotherapy and 44% among those who did not. 

The analysis can't establish that therapy drove the difference, and the authors note that unmeasured factors could have shaped both who reached treatment and how they fared. Depression itself was tied to an 11% higher risk of cancer death. One year after diagnosis, 29% of patients with depression had died of their cancer, compared with 21% of those without it. At five years the gap held: 43% versus 35%. 

Antidepressants reached far more patients, 32.5% within four weeks, but showed no tie to cancer mortality in the cohort-wide analysis. Depression carried higher cancer-specific mortality in all six cancers examined, strongest in prostate cancer. The psychotherapy association held for prostate, breast, and kidney cancer, and antidepressants were tied to lower mortality in prostate cancer alone. 

Researchers drew 265,639 Medicare beneficiaries age 66 or older from SEER-Medicare, diagnosed from 2010 to 2017 with breast, colorectal, prostate, bladder, kidney, or non-small cell lung cancer; 22% had a preexisting major depressive disorder diagnosis. Psychotherapy was identified through Medicare procedure codes and antidepressants through Part D claims, with mortality associations adjusted by propensity score weighting. 

With a third of patients starting antidepressants within a month, clinicians appear willing to address depression. But referral pathways that can connect patients with therapy within four weeks remain limited. Although the magnitude of benefit varied by cancer type, the overall findings support integrating depression care into oncology from the first visit and tailoring it to the patient's cancer, prognosis, and treatment course.

"Depression is common among people facing cancer, but it is often under recognized and undertreated. This study shows that timely treatment for depression is associated with better cancer survival," said Fumiko Chino, MD, a radiation oncologist at The University of Texas MD Anderson Cancer Center in Houston. "Patients who received treatment within 1 month of diagnosis had a lower risk of cancer death; it also shows that psychotherapy may potentially be underutilized given larger benefits over medication. Tailored and appropriate screening and referral for mental health care is an essential part of life-saving oncology care." 

Source: Qiao EM, et al. (2026 Sep 28) American Society for Radiation Oncology Annual Meeting 2026, Abstract 195. Role of Early Mental Health Interventions on Cancer Mortality for Patients with Depression